Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations

[1]  M. Peiris,et al.  SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  Justine C. Williams,et al.  Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine , 2022, Cell.

[3]  D. Harats,et al.  Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron , 2022, The New England journal of medicine.

[4]  D. Barouch,et al.  Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants , 2022, The New England journal of medicine.

[5]  N. Klopp,et al.  Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany , 2022, Frontiers in Immunology.

[6]  M. Koopmans,et al.  Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients , 2022, Science Immunology.

[7]  S. Vermund,et al.  Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination , 2022, Nature Medicine.

[8]  L. Poon,et al.  Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination , 2022, Nature Medicine.

[9]  K. Swanson,et al.  Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera , 2022, Science.

[10]  D. von Laer,et al.  SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons , 2022, The New England journal of medicine.

[11]  K. Schenke-Layland,et al.  Antibody binding and ACE2 binding inhibition is significantly reduced for the Omicron variant compared to all other variants of concern , 2022, medRxiv.

[12]  F. Baldanti,et al.  Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant , 2021, BMC Medicine.

[13]  H. Jäck,et al.  The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic , 2021, Cell.

[14]  M. Nussenzweig,et al.  Plasma Neutralization of the SARS-CoV-2 Omicron Variant , 2021, The New England journal of medicine.

[15]  D. Khoury,et al.  SARS-CoV-2 Omicron: reduction of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern , 2021, medRxiv.

[16]  J. Mascola,et al.  Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization , 2021, medRxiv.

[17]  Christina C. Chang,et al.  mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant , 2021, medRxiv.

[18]  O. Tsang,et al.  Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients , 2021, medRxiv.

[19]  M. Nussenzweig,et al.  Plasma neutralization properties of the SARS-CoV-2 Omicron variant , 2021, medRxiv.

[20]  J. Kimpel,et al.  SARS-CoV-2 B.1.1.529 variant (Omicron) evades neutralization by sera from vaccinated and convalescent individuals , 2021, medRxiv.

[21]  J. Nie,et al.  The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron , 2021, Emerging microbes & infections.

[22]  A. Sigal,et al.  SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection , 2021, medRxiv.

[23]  S. Hoehl,et al.  Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies , 2021, medRxiv.

[24]  G. Screaton,et al.  Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum , 2021, The Lancet.

[25]  J. Lopez Bernal,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply. , 2021, The New England journal of medicine.

[26]  Y. Kemmling,et al.  SARS-CoV-2 Seroprevalence in Germany. , 2021, Deutsches Arzteblatt international.

[27]  Philip L. Tzou,et al.  The biological and clinical significance of emerging SARS-CoV-2 variants , 2021, Nature Reviews Genetics.

[28]  P. Sullivan,et al.  Trajectory of COVID-19 Vaccine Hesitancy Over Time and Association of Initial Vaccine Hesitancy With Subsequent Vaccination , 2021, JAMA network open.

[29]  L. Tserel,et al.  Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study , 2021, The Lancet Regional Health - Europe.

[30]  L. Heylen,et al.  Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. , 2021, JAMA.

[31]  R. Myers,et al.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.

[32]  F. Krammer.  A correlate of protection for SARS-CoV-2 vaccines is urgently needed , 2021, Nature Medicine.

[33]  J. Vekemans,et al.  Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[34]  J. Farrar,et al.  Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom , 2021, Nature Medicine.

[35]  S. S. Sohrab,et al.  Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay , 2021, Diagnostics.

[36]  A. Rodger,et al.  Spike-antibody responses to ChAdOx1 and BNT162b2 vaccines by demographic and clinical factors (Virus Watch study) , 2021 .

[37]  H. Jäck,et al.  SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies , 2021, Cell.

[38]  D. Altmann,et al.  Immunity to SARS-CoV-2 variants of concern , 2021, Science.

[39]  H. Rammensee,et al.  Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity , 2021, Nature Communications.

[40]  H. Jäck,et al.  SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization , 2021, bioRxiv.

[41]  A. Manenti,et al.  Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation Assays , 2020, Viruses.

[42]  R. Trimble.  COVID-19 Dashboard , 2020 .

[43]  B. Graham,et al.  Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization , 2018, Journal of Virology.

[44]  Inga Nehlmeier,et al.  The glycoprotein of vesicular stomatitis virus promotes release of virus-like particles from tetherin-positive cells , 2017, PloS one.

[45]  G. Zimmer,et al.  A Vesicular Stomatitis Virus Replicon-Based Bioassay for the Rapid and Sensitive Determination of Multi-Species Type I Interferon , 2011, PloS one.